Increased adherence to influenza vaccination among Palermo family pediatricians: a study on safety and compliance of qLAIV vaccination.
Humans
Influenza Vaccines
/ administration & dosage
Influenza, Human
/ prevention & control
Male
Pediatricians
Female
Italy
Vaccination
Health Knowledge, Attitudes, Practice
Guideline Adherence
Surveys and Questionnaires
Adult
Vaccination Coverage
/ statistics & numerical data
Sicily
Child
Attitude of Health Personnel
Influenza
Pediatrics
Safety
Vaccination
qLAIV
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
11 Jul 2024
11 Jul 2024
Historique:
received:
14
05
2024
accepted:
09
06
2024
medline:
11
7
2024
pubmed:
11
7
2024
entrez:
10
7
2024
Statut:
epublish
Résumé
Influenza represents a serious public health threat, especially for the management of severe cases and complications of the disease, requiring the implementation of control measures. We aimed to assess the acceptance and impact of qLAIV vaccination among a representative sample of family paediatricians (FPs) operating in Palermo Local Health Authority (LHA). To this end we evaluated vaccination coverage rates, comparing it with that observed in Sicilian context, while actively monitoring possible adverse reactions and their severity. An observational descriptive non-controlled study was conducted in two phases, from September 2022 to June 2023. The first phase involved a formative and educational intervention with a pre-intervention questionnaire to assess the knowledge and attitudes of FPs on paediatric influenza vaccination. The second phase consisted of an active surveillance on qLAIV safety and acceptance among the paediatric population assisted by the participating FPs, from October 2022 to April 2023. Frequencies, chi-squared tests, and comparisons statistics were performed using Stata/MP 14.1. The overall coverage rate among the paediatric population involved in the intervention was 13.2%, with an I.M./qLAIV ratio of vaccine administered of 1/4.25. This coverage rate was significantly higher (p-value <0.001) when compared to the average values reported in the population under the Palermo Local Health Authority (LHA) (6.7%) and in the entire Sicily (5.9%). Adverse events in the qLAIV group were mild, with only 3.3% experiencing them, primarily presenting as a feverish rise (3.2%). No severe adverse reaction was reported. The educational intervention significantly raised paediatric influenza vaccination rates among the participating FPs, and in general improved influenza vaccination coverage rates in the Palermo's LHU. Minimal, non-serious adverse events underscored the vaccine's safety. Training sessions ensured paediatricians stayed informed, enabling them to provide comprehensive information to parents for secure and informed vaccination decisions in their practices.
Sections du résumé
BACKGROUND
BACKGROUND
Influenza represents a serious public health threat, especially for the management of severe cases and complications of the disease, requiring the implementation of control measures. We aimed to assess the acceptance and impact of qLAIV vaccination among a representative sample of family paediatricians (FPs) operating in Palermo Local Health Authority (LHA). To this end we evaluated vaccination coverage rates, comparing it with that observed in Sicilian context, while actively monitoring possible adverse reactions and their severity.
METHODS
METHODS
An observational descriptive non-controlled study was conducted in two phases, from September 2022 to June 2023. The first phase involved a formative and educational intervention with a pre-intervention questionnaire to assess the knowledge and attitudes of FPs on paediatric influenza vaccination. The second phase consisted of an active surveillance on qLAIV safety and acceptance among the paediatric population assisted by the participating FPs, from October 2022 to April 2023. Frequencies, chi-squared tests, and comparisons statistics were performed using Stata/MP 14.1.
RESULTS
RESULTS
The overall coverage rate among the paediatric population involved in the intervention was 13.2%, with an I.M./qLAIV ratio of vaccine administered of 1/4.25. This coverage rate was significantly higher (p-value <0.001) when compared to the average values reported in the population under the Palermo Local Health Authority (LHA) (6.7%) and in the entire Sicily (5.9%). Adverse events in the qLAIV group were mild, with only 3.3% experiencing them, primarily presenting as a feverish rise (3.2%). No severe adverse reaction was reported.
CONCLUSIONS
CONCLUSIONS
The educational intervention significantly raised paediatric influenza vaccination rates among the participating FPs, and in general improved influenza vaccination coverage rates in the Palermo's LHU. Minimal, non-serious adverse events underscored the vaccine's safety. Training sessions ensured paediatricians stayed informed, enabling them to provide comprehensive information to parents for secure and informed vaccination decisions in their practices.
Identifiants
pubmed: 38987808
doi: 10.1186/s13052-024-01693-y
pii: 10.1186/s13052-024-01693-y
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
126Informations de copyright
© 2024. The Author(s).
Références
Ministero della Salute. Prevenzione e controllo dell’influenza: raccomandazioni per la stagione 2022–202. Available on: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2022&codLeg=87997&parte=1 &serie=null
World Health Organization. Importance of measuring influenza burden of disease. Available on: https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/burden-of-disease
Istituto Superiore di Sanità. EpiCentro - L’epidemiologia per la sanità pubblica. Influenza. Available on: https://www.epicentro.iss.it/influenza/epidemiologia-europa
Istituto Superiore di Sanità. EpiCentro - L’epidemiologia per la sanità pubblica. Informazioni generali. Available on: https://www.epicentro.iss.it/influenza/influenza
Gregg M, Blackhouse G, Loeb M, Goeree R. Economic evaluation of an influenza immunization strategy of healthy children. Int J Technol Assess Health Care. 2014;30(4):394–9. https://doi.org/10.1017/S0266462314000397
doi: 10.1017/S0266462314000397
pubmed: 25412647
King JC, Lichenstein R, Cummings GE, Magder LS. Impact of influenza vaccination of schoolchildren on medical outcomes among all residents of Maryland. Vaccine. 2010;28(49):7737–42. https://doi.org/10.1016/j.vaccine.2010.09.064
doi: 10.1016/j.vaccine.2010.09.064
pubmed: 20933566
MedImmune. Fluenz
MedImmune LLC. Apr. FluMist
AstraZeneca Canada. FluMist
Skwarczynski M, Toth I. Non-invasive mucosal vaccine delivery: advantages, challenges and the future. Expert Opin Drug Deliv. 2020;17(4):435.
doi: 10.1080/17425247.2020.1731468
pubmed: 32059625
Smith KJ, Raviotta JM, DePasse JV, Brown ST, Shim E, Patricia Nowalk M, Zimmerman RK. Cost effectiveness of influenza vaccine choices in children aged 2–8 years in the U.S. Am J Prev Med. 2016;50(5):600–8. https://doi.org/10.1016/j.amepre.2015.12.010
doi: 10.1016/j.amepre.2015.12.010
pubmed: 26868283
pmcid: 4841730
Shim E, Brown ST, DePasse J, Nowalk MP, Raviotta JM, Smith KJ, et al. Cost effectiveness of influenza vaccine for U.S. children. Am J Prev Med. 2016;51(3):309.
doi: 10.1016/j.amepre.2016.02.027
pubmed: 27079638
pmcid: 5384696
Vaccinazione antinfluenzale. 2022–2023 - Coperture Vaccinali per 100 abitanti. Available on: https://www.salute.gov.it/imgs/C_17_tavole_19_5_1_file.pdf
ISTAT. Il Censimento permanente della popolazione in Sicilia - Anno 2020. Available on: https://www.istat.it/it/archivio/268007 (Last accessed 15/02/2024).
Gazzetta Ufficiale dell’Unione Europea. REGOLAMENTO (UE) N. 536/2014 DEL PARLAMENTO EUROPEO E DEL CONSIGLIO del 16 Aprile. 2014 Sulla Sperimentazione Clinica di Medicinali per uso Umano e che abroga la Direttiva 2001/20/CE. Available online: https://eur-lex.europa.eu/legal-content/IT/TXT/PDF/?uri=CELEX:32014R0536 &from=FR (accessed on 30 December 2023).
Singh H, Chase AJ. Measuring vaccine acceptance and knowledge within health professions education. Vaccine. 2022;40(37):5452–8. https://doi.org/10.1016/j.vaccine.2022.07.039 . Epub 2022 Aug 4. PMID: 35933277.
doi: 10.1016/j.vaccine.2022.07.039
pubmed: 35933277
Boom JA, Nelson CS, Laufman LE, Kohrt AE, Kozinetz CA. Improvement in provider immunization knowledge and behaviors following a peer education intervention. Clin Pediatr. 2007;46:706–17.
doi: 10.1177/0009922807301484
Briss PA, Rodewald LE, Hinman AR, et al. Reviews ofevidence regarding interventions to improve vaccinationcoverage in children, adolescents, and adults: the taskforce on community preventive services. Am J PrevMed. 2000;18:97–140.
doi: 10.1016/S0749-3797(99)00118-X
Pope S, Rader A, Stansifer S. Assessing vaccine hesitancy among pediatric healthcare providers. J Dr Nurs Pract. 2022;15(1):65–71. https://doi.org/10.1891/JDNP-2021-0033 . PMID: 35228346.
Stephens AB, Hofstetter AM, Stockwell MS. Influenza vaccine hesitancy: scope, influencing factors, and strategic interventions. Pediatr Clin North Am. 2023;70(2):227–241. https://doi.org/10.1016/j.pcl.2022.11.003 . PMID: 36841592.
Fluenz Tetra nasal. spray suspension Influenza vaccine (live attenuated, nasal). SUMMARY OF PRODUCT CHARACTERISTICS. Available on: https://www.ema.europa.eu/en/documents/product-information/fluenz-tetra-epar-product-information_it.pdf
Rahmati R, Khadivzadeh T, Esmaily H. Comparison of the effect of two training methods (webinar and group discussion) on improving the attitude and performance of health workers in providing counseling with fertility promotion approach. J Educ Health Promot. 2020;9:280. https://doi.org/10.4103/jehp.jehp_134_20 . PMID: 33282985; PMCID: PMC7709760.
doi: 10.4103/jehp.jehp_134_20
pubmed: 33282985
pmcid: 7709760
Arrigoni L, Boogaard C, Strohm-Farber J, J Pediatr Health Care. A Webinar to improve parental COVID-19 vaccine hesitancy. 2023 Nov-Dec;37(6):590–8. https://doi.org/10.1016/j.pedhc.2023.03.003 . Epub 2023 Mar 16. PMID: 37024370; PMCID: PMC10017383.
Leong JMC, Lam WL, Tan SZ, Ng CY. Changing face of medical education during a pandemic: tragedy or opportunity? Postgrad Med J. 2022;98(1161):492–8. https://doi.org/10.1136/postgradmedj-2021-140330 . Epub 2021 Jun 30. PMID: 34193542.
doi: 10.1136/postgradmedj-2021-140330
pubmed: 34193542
Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist
.Centers for Disease Control and Prevention. Available on: https://archive.cdc.gov/#/details?url=https://www.cdc.gov/media/releases/2014/p0327-flu-study.html
Jill M. Ferdinands and others, effectiveness of Influenza Vaccine against Life-threatening RT-PCR-confirmed Influenza illness in US children, 2010–2012, the Journal of Infectious diseases, 210, issue 5, 1 September 2014, Pages 674–83, https://doi.org/10.1093/infdis/jiu185
Turner PJ, Fleming L, Saglani S, Southern J, Andrews NJ, Miller E. SNIFFLE-4 study investigators. Safety of live attenuated influenza vaccine (LAIV) in children with moderate to severe asthma. J Allergy Clin Immunol. 2020;145(4):1157–e11646. https://doi.org/10.1016/j.jaci.2019.12.010 . Epub 2019 Dec 18. PMID: 31863808; PMCID: PMC7156909.
doi: 10.1016/j.jaci.2019.12.010
pubmed: 31863808
pmcid: 7156909
Flood EM, Ryan KJ, Rousculp MD, Beusterien KM, Divino VM, Block SL, Hall MC, Mahadevia PJ. Parent preferences for pediatric influenza vaccine attributes. Clin Pediatr (Phila). 2011;50(4):338–47. Epub 2010 Dec 30. PMID: 21196417.
doi: 10.1177/0009922810391247
pubmed: 21196417
Pavlovic D, Sahoo P, Larson HJ, Karafillakis E. Factors influencing healthcare professionals’ confidence in vaccination in Europe: a literature review. Hum Vaccin Immunother. 2022;18(1):2041360. https://doi.org/10.1080/21645515.2022.2041360 . Epub 2022 Mar 15. PMID: 35290160; PMCID: PMC9009961.
doi: 10.1080/21645515.2022.2041360
pubmed: 35290160
pmcid: 9009961